Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Shares Outstanding (Weighted Average) (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Shares Outstanding (Weighted Average) for 17 consecutive years, with $58.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 1.34% to $58.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58.9 million through Dec 2025, up 1.34% year-over-year, with the annual reading at $58.9 million for FY2025, 1.34% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $58.9 million in Q4 2025 for Vanda Pharmaceuticals, roughly flat from $59.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $59.1 million in Q3 2025 to a low of $55.1 million in Q1 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $57.2 million across 5 years, with a median of $57.3 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 2.49% in 2021 and later rose 1.0% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $55.5 million in 2021, then grew by 1.64% to $56.5 million in 2022, then grew by 1.63% to $57.4 million in 2023, then increased by 1.34% to $58.1 million in 2024, then increased by 1.34% to $58.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for VNDA at $58.9 million in Q4 2025, $59.1 million in Q3 2025, and $59.0 million in Q2 2025.